Lawrence Green, MD, section editor of The Dermatologist’s Psoriasis Center of Excellence and clinical professor at George Washington School of Medicine, shares his pearls on implementing the National Psoriasis Foundation’s treat-to-target approach.

There are many questions regarding the best way to manage patients with psoriasis during the coronavirus pandemic, particularly patients on systemic therapies. Dr Lawrence Green discusses how to address patients’ concerns, maintaining a safe work environment if you choose to keep your practice open, and current recommendations for patients on biologics, including anti‑TNF inhibitors.

New and emerging therapies such as biologics continue to improve quality of life and outcomes for patients with psoriasis. Biologics that block IL-23 functions present a unique opportunity to provide long-term, effective treatment.

The link between cardiovascular disease and psoriasis is no longer novel, but the role of psoriasis therapies in improving both diseases is still under investigation. Dr Hawley discusses the importance of treating more than just the skin among patients with psoriasis.

Adolescence, an already-difficult time in one's life, can be further complicated by psoriasis. Dr Lawrence Green, with George Washington University School of Medicine, discusses his treatment strategies for managing psoriasis in teenagers.

Kristi B. Hawley, DO, FAOCD, discusses the management of psoriasis in women who are pregnant or breastfeeding.

Certain comorbidities—particularly congestive heart failure, tuberculosis, and HIV infection—can affect the type of psoriasis treatment physicians recommend to their patients.

Access restrictions to therapies among patients with rheumatoid arthritis and psoriatic arthritis can significantly impact treatment effectiveness and adherence. Natalie Boytsov, PhD, discussed the implications of these restrictions with The Dermatologist.

Lawrence Green, MD, shares his perspective on a recent article that showed step therapy and prior authorizations negatively impacted patient care and treatment adherence.  

While anti-tumor necrosis factor (TNF) inhibitors are effective treatments for patients with several inflammatory diseases, they may be associated with new onset psoriatic eruptions or paradoxical worsening of preexisting psoriatic skin disease. In an interview with The Dermatologist, Lourdes M. Perez-Chada, MD, MMSc, Sara Jiayang Li, BS, and Joseph F. Merola, MD, MMSc, discuss a novel treatment algorithm for managing patients treated with anti-TNF inhibitors who develop this adverse event.